Belatacept Post Depletional Repopulation to Facilitate Tolerance
Use of Belatacept During Post Depletional Repopulation to Facilitate Tolerance in Renal Allograft Recipients
Sponsor: Allan D Kirk, MD, PhD
This PHASE2 trial investigates Organ Transplantation and is currently completed. Allan D Kirk, MD, PhD leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allan D Kirk, MD, PhD
- Bristol-Myers Squibb
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .